Core Viewpoint - The article highlights the significant growth of the sugar substitute stock, Bailong Chuangyuan (605016.SH), following the approval and application of allulose sugar in China, with a reported 48.9% increase in net profit for 2025 [3][5]. Group 1: Company Performance - Bailong Chuangyuan reported a revenue of 1.38 billion yuan for 2025, marking a year-on-year increase of 19.8% [3]. - The company's net profit attributable to shareholders reached 370 million yuan, reflecting a 48.9% year-on-year growth [3]. - The growth is attributed to an optimized product structure, with a higher sales proportion of high-margin resistant dextrin products, and cost reductions from technological upgrades [3][5]. Group 2: Market Trends and Product Development - The approval of allulose sugar as a new food ingredient in China is expected to drive demand, with projections estimating a domestic demand of 150,000 to 200,000 tons over the next 3-5 years [5]. - Major food and beverage companies, such as Mengniu, are accelerating the application of allulose sugar in their products, with some already testing allulose sugar formulations [5]. - Despite the high cost of allulose sugar compared to erythritol, which is 2-3 times higher, improvements in extraction efficiency are anticipated to gradually lower costs [6]. Group 3: Industry Challenges - The past two years have seen a slowdown in the performance of sugar substitute companies due to the chaotic expansion of erythritol production, leading to a drop in raw material prices [5]. - Companies like San Yuan Biological and Baolingbao are now focusing on allulose sugar to regain market momentum [5].

Group 1 - The core viewpoint of the news is the significant growth in the performance of sugar substitute company Bailong Chuangyuan, with a 48.9% increase in net profit for 2025, driven by the approval and application of allulose sugar in China [1] - Bailong Chuangyuan reported a revenue of 1.38 billion yuan for 2025, representing a year-on-year growth of 19.8%, and a net profit of 370 million yuan, reflecting a 48.9% increase compared to the previous year [1] - The company's performance growth is attributed to an optimized product structure, with a higher sales proportion of high-margin resistant dextrin products, as well as cost reductions from technological upgrades and improved capacity utilization [1] Group 2 - The National Health Commission of China officially approved allulose sugar as a new food raw material in July 2025, which is expected to have a demand of 150,000 to 200,000 tons in the domestic market over the next 3-5 years [2] - Following the approval, food and beverage companies in China are accelerating the application of allulose sugar in their products, with brands like Mengniu's Youyi C zero-sugar series being the first to adopt this ingredient on a large scale [2] - Despite the high cost of allulose sugar compared to erythritol, which is 2-3 times higher, several major sugar substitute companies are expanding their production or planning to enter the allulose sugar market to regain competitive advantage [2][3] Group 3 - Current market prices for allulose sugar range from 28,000 to 30,000 yuan per ton, while erythritol is priced between 9,000 and 10,000 yuan per ton, indicating a significant cost disparity [3] - Improvements in technology have led to enhanced conversion and extraction efficiency for allulose sugar, resulting in a decrease in its price, although it remains high compared to erythritol [3] - The market performance of allulose sugar post-launch is still uncertain, as its higher production costs may impact its widespread adoption [3]